Roles of adipokines in liver injury and fibrosis

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 1, 2008, Pages 47-57

  Wang, Jianhua ^a   Brymora, Joanne ^a   George, Jacob ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adipokines; Adiponectin; Hepatic stellate cells; Kupffer cells; Leptin; Liver fibrosis; Resistin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; JANUS KINASE; LEPTIN; LEPTIN RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN; RESISTIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOL ABUSE; CYTOKINE PRODUCTION; GENE EXPRESSION; HEPATITIS B; HEPATITIS C; HUMAN; INSULIN RESISTANCE; KUPFFER CELL; LIVER FIBROSIS; LIVER INJURY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; STELLATE CELL;

ADIPOKINES; HUMANS; LIVER CIRRHOSIS;

EID: 49149119288     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.1.47     Document Type: Review

References (68)

1. Anthony PP, Ishak KG, Nayak NC et al. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J. Clin. Pathol. 31, 395-414 (1978).
2. Bissell DM, Roulot D, George J. Transforming growth factor β and the liver. Hepatology 34, 859-867 (2001).
3. Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest. 115, 209-218 (2005)
4. Fatty Liver Disease: NASH and Related Disorders. Farrell GC, George J, Hall P et al. (Eds). Blackwell Publishing, Oxford, UK, 1-319 (2005).
5. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387-1395 (2004).
6. McCullough AJ. The epidemiology and risk factors of NASH. In: Fatty Liver Disease: NASH and Related Disorders. Farrell GC, George J, Hall P et al. Blackwell Publishing, Oxford, UK, 23-37 (2005).
7. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35, 373-379 (2002).
8. Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107, 450-455 (1999).
9. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120, 1183-1192 (2001).
10. Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function? J. Physiol. Pharmacol. 57, 505-528 (2006).
11. Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J. 393(Pt 1), 7-20 (2006).
12. Potter JJ, Womack L, Mezey E, Anania FA. Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem. Biophys. Res. Commun. 244, 178-182 (1998)
13. Wolf G, Ziyadeh F. Leptin and renal fibrosis. In: Obesity and the Kidney. Wolf G (Ed.). Karger, Basel, Switzerland, 175-183 (2006).
14. Leclercq IA, Farrell GC, Schriemer R et al. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J. Hepatol. 37, 206-213 (2002).
15. Ikejima K, Honda H, Yoshikawa M et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 34, 288-297 (2001).
16. Potter JJ, Rennie-Tankesley L, Mezey E. Influence of leptin in the development of hepatic fibrosis produced in mice by Schistosoma mansoni infection and by chronic carbon tetrachloride administration. J. Hepatol. 38, 281-288 (2003).
17. Ding X, Saxena NK, Lin S et al. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am. J. Pathol. 166, 1655-1669 (2005).
18. Sahai A, Malladi P, Pan X et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of non-alcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am. J. Physiol. Gastrointest. Liver Physiol. 28, G1035-G1043 (2004).
19. McCullough AJ, Bugianesi E, Marchesini G, Kalhan SC. Gender-dependent alterations in serum leptin in alcoholic cirrhosis. Gastroenterology 115, 947-953 (1998).
20. Nobili V, Manco M, Ciampalini P et al. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. Eur. J. Endocrinol. 155(5), 735-743 (2006).
21. Bolukbas FF, Bolukbas C, Horoz M et al. Chad-Pugh classification dependent alterations in serum leptin levels among cirrhotic patients: a case controlled study. BMC Gastroenterol. 23, 4-23 (2004).
22. Chalasani N, Crabb DW, Cummings OW et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am. J. Gastroenterol. 98, 2771-2776 (2003).
23. Chitturi S, Farrell G, Frost L et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 36, 403-409 (2002).
24. Ockenga J, Bischoff SC, Tillmann HL et al. Elevated bound leptin correlates with energy expenditure in cirrhotics. Gastroenterology 119, 1656-1662 (2000).
25. Bethanis SK, Theocharis SE. Leptin in the field of hepatic fibrosis: a pivotal or an incidental player? Dig. Dis. Sci. 51, 1685-1696 (2006).
26. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 35, 762-771 (2002).
27. Aleffi S, Petrai I, Bertolani C et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 42, 1339-1348 (2005).
28. Cao Q, Mak EM, Lieber CS. Leptin represses matrix metalloproteinase-1 gene expression in LX2 human hepatic stellate cells. J. Hepatol. 46, 124-133 (2007).
29. 2-dependent MAPK pathways. J. Cell Biochem. 97, 188-197 (2006).
30. 2-dependant MAPK pathways. J. Biol. Chem. 279, 4292-4304 (2004).
31. Saxena NK, Titus MA, Ding X et al. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J. 18, 1612-1614 (2004).
32. Lang T, Ikejima K, Yoshikawa M et al. Leptin facilitates proliferation of hepatic stellate cells through up-regulation of platelet-derived growth factor receptor. Biochem. Biophys. Res. Commun. 323, 1091-1095 (2004).
33. Qamar A, Sheikh SZ, Masud A et al. In vitro and in vivo protection of stellate cells from apoptosis by leptin. Dig. Dis. Sci. 51, 1697-1705 (2006).
34. Ikejima K, Takei Y, Honda H et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122, 1399-1410 (2002).
35. Tang M, Potter JJ, Mezey E. Leptin enhances the effect of transforming growth factor β in increasing type I collagen formation. Biochem. Biophys. Res. Commun. 297, 906-911 (2002).
36. Wang J, Leclercq I, Brymora J et al. Kupffer cells: the main player in leptin-induced liver fibrosis. J. Gastroenterol. Hepatol. A315 (2006).
37. Motoshima H, Wu X, Sinha MK et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J. Clin. Endocrinol. Metab. 87, 5662-5667 (2002).
38. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and Type 2 diabetes: dose association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86, 1930-1935 (2001).
39. Coop M, Havel PJ, Utzschneider KM et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46, 459-469 (2003).
40. Gavrila A, Chan JL, Yiannakouris N et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J. Clin. Emdocrinol. Metab. 88, 4823-4831 (2003).
41. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in Type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20, 1595-1599 (2000).
42. Hotta K Funahashi T, Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to Type 2 diabetes in rhesus monkeys. Diabetes 50, 1126-1133 (2001).
43. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J. Am. Soc. Nephrol. 13, 134-141 (2002).
44. Kumada M, Kihara S, Sumitsuji S et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb, Vasc. Biol. 23, 85-89 (2003).
45. Ouchi N, Kihara S, Arita Y et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation 102, 1296-1301 (2000).
46. Kobashi C, Urakaze M, Kishida M et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ. Res. 97, 1245-1252 (2005).
47. Yokota T, Oritani K, Takahashi I et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96, 1723-1732 (2000).
48. Arita Y, Kihara S, Ouchi N et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105, 2893-2898 (2002).
49. Wolf AM, Wolf D, Rumpold H et al. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biopbys. Res. Commun. 323, 630-635 (2004).
50. Xu A, Wang Y, Keshaw H et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 112, 91-100 (2003).
51. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8, 1288-1295 (2002).
52. Masaki T, Chiba S, Tatsukawa H et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-α in KK-Ay obese mice. Hepatology 40, 177-184 (2004).
53. Kamada Y, Tamura S, Kiso S et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125, 1796-1807 (2003).
54. Neumeier M, Hellerbrand C, Gabele E et al. Adiponectin and its receptors in rodent models of fatty liver disease and liver cirrhosis. World J. Gastroenterol. 12, 5490-5494 (2006).
55. Thakur V, Pritchard MT, McMullen MR, Nagy LE. Adiponectin normalizes LPS-stimulated TNF-α production by rat Kupffer cells after chronic ethanol feeding. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G998-1007 (2006).
56. Bugianesi E, Pagotto U, Manini R et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J. Clin. Endcorinol. Metab. 90, 3498-3504 (2005).
57. Kamada Y, Matsumoto H, Tamura S et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J. Hepatol. (2007) (Epub ahead of print).
58. Hui JM, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 40, 46-54 (2004).
59. Lopez-Bermejo A, Botas P, Funahashi T et al. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin. Endocrino. (Oxf.) 60, 256-263 (2004).
60. Kaser S, Moschen A, Cayon A et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54, 117-121 (2005).
61. Cua IH, Hui JM, Bandara P et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 46, 66-73 (2007).
62. Kaser S, Moschen A, Kaser A et al. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J. Intern. Med. 258, 274-280 (2005).
63. Hui CK, Zhang HY, Lee NP et al. Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. J. Hepatol. 47, 191-202 (2007).
64. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 409, 307-312 (2001).
65. Bertolani C, Sancho-Bru P, Failli P et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am. J. Pathol. 169, 2042-2053 (2006).
66. Yagmur E, Trautwein C, Gressner AM, Tacke F. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am. J. Gastroenterol. 101, 1244-1252 (2006).
67. Bahr MJ, Ockenga J, Boker KH, Manns MP, Tietge UJ. Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance. Am. J. Physiol. Endocrinol. Metab. 291, E199-E206 (2006).
68. She H, Xiong S, Hazra S, Tsukamoto H. Adipogenic transcriptional regulation of hepatic stellate cells. J. Biol. Chem. 280, 4959-4967 (2005).